维普中文期刊产品整合服务
1篇 您的检索式:作者名="Chanjun Zhen"
    题名 作者 年代 出处 被引量
1Prognostic factors for patients with limited-stage small-cell lung cancer without receiving prophylactic cranial irradiation显示文摘Objective:This retrospective study aims to explore the risk factors for brain metastasis and the prognostic factors for overall survival(OS)in patients with limited-stage small-cell lung cancer(LS-SCLC)who have no brain metastases according to magnetic resonance imaging(MRI)and have not received prophylactic cranial irradiation(PCI)after first-line chemoradiotherapy.Methods:A total of 107 patients who were treated in the Fourth Hospital of Hebei Medical University from January 2013 to December 2017 were enrolled in this study.The patients were treated with etoposide/platinum chemotherapy and thoracic radiotherapy(TRT)with involved-field irradiation.The median dose of the radiotherapy was 60 Gy(50-64 Gy).The primary study endpoints include BMFS(brain-metastasis-free survival)and OS(overall survival).The Kaplan-Meier method was applied to estimate survival,with a log-rank test used to ascertain statistical significance.The multivariate Cox proportional hazards model was used to determine the prognostic factors for survival.Results:The median follow-up of all patients was 18.8 months(range:7.9–65.1 months)and the median follow-up of surviving patients was 26.7 months(range:18.8–65.1 months).The median OS of the whole cohort was 20.1 months,and the 1-,2-and 3-year OS rates were 84.9%,44.9%,and 25.9%,respectively.The 1-,2-,and 3-year BMFS rates were 69.0%,49.9%,and 40.7%,respectively.50 patients(46.7%)developed brain metastases during the follow-up period,and the median time from the start to brain metastasis was 10.7 months(range:4.8–31.1 months).As shown by multivariate analysis,independent prognostic factors of OS included cycles of chemotherapy(P=0.019),the response to initial treatment(P=0.011),and the start time of TRT(P=0.044).The independent prognostic factors of BMFS included the clinical stage(P=0.008),the response to initial treatment(P=0.024),and the start time of TRT(P=0.028).Conclusions:For patients with LS-SCLC who have not received PCI,favorable factors for lower brain metastasis and higher survival include early clinical stage,CR to initial chemoradiotherapy,early TRT,and adequate cycles of chemotherapy.PCI is still recommended as the standard modality since the incidence of brain metastases was high(46.7%).Cuimin Ding Jing Li Shuoshuo Wang Chen Yang Rui Zhang Wenwen Bai Ming Liu Chanjun Zhen Xueying Qiao 2020Radiation Medicine and Protection2020,1,2:0
返回顶部 每页显示:
共1页 首页 上一页 第1页 下一页 末页 /1 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费